Hepatobiliary Surgery and Nutrition · 2 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review discusses conversion therapy for advanced cholangiocarcinoma, summarizing that a phase 1b/2 study of silmitasertib plus gemcitabine-cisplatin chemotherapy improved progression-free survival compared to chemotherapy alone.
This narrative review evaluates conversion therapy strategies for advanced cholangiocarcinoma (CCA). The review focuses on a published phase 1b/2 trial of silmitasertib plus GemCis, which showed a median PFS of 11.2 months versus 5.7 months for GemCis alone, with an ORR of 34%. It also summarizes other combination therapies, such as durvalumab with chemotherapy and lenvatinib/toripalimab with chemotherapy, reporting varying ORRs and some successful conversion surgeries. The review notes that the efficacy of therapies may differ based on tumor location and underlying genetic mutations. The implication is that novel therapies may enhance conversion rates and prognosis for unresectable CCA.
